Document is current
Any future updates will be listed below
-
Authors
Sullivan, Mark R. http://orcid.org/0000-0001-5765-0459
Darnell, Alicia M.
Reilly, Montana F.
Kunchok, Tenzin
Joesch-Cohen, Lena
Rosenberg, Daniel
Ali, Ahmed
Rees, Matthew G.
Roth, Jennifer A. http://orcid.org/0000-0002-5117-5586
Lewis, Caroline A. http://orcid.org/0000-0003-1787-5084
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32-GM007287)
MIT Koch Graduate Fellowship
Jane Coffin Childs Memorial Fund for Medical Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA242379, R01CA201276, P30CA014051)
EIF | Stand Up To Cancer
Lustgarten Foundation
Howard Hughes Medical Institute (Faculty Scholars Grant)
The Ludwig Center at MIT, the MIT Center for Precision Cancer Medicine, the Emerald Foundation
- License Information
-
More Information
Article History
Received: 13 October 2020
Accepted: 27 September 2021
First Online: 18 November 2021
Competing interests
: M.G.V.H. is on the scientific advisory board of Agios Pharmaceuticals, Aeglea Biotherapeutics, iTeos Therapeutics, Faeth Therapeutics, Sage Therapeutics, DRIOA Ventures and Auron Therapeutics. The other authors declare no competing interests.
